

PAGE: 1

**RAW SEQUENCE LISTING
PATENT APPLICATION US/08/447,118A**DATE: 92/28/97
TIME: 18:04:52**INPUT SET: S15870.raw**

This Raw Listing contains the General Information Section and up to the first 5 pages.

SEQUENCE LISTING

Does Not Comply
Corrected Diskette Needed

- 1
2
3 (1) General Information:
4
5 (i) APPLICANT:
6 (A) NAME: Burkly, Linda C.
7 (B) STREET: 34 Winthrop Street
8 (C) CITY: West Newton
9 (D) STATE: Massachusetts
10 (E) COUNTRY: USA
11 (F) POSTAL CODE (ZIP): 02165
12
13 (A) NAME: Biogen, Inc.
14 (B) STREET: Fourteen Cambridge Center
15 (C) CITY: Cambridge
16 (D) STATE: Massachusetts
17 (E) COUNTRY: USA
18 (F) POSTAL CODE (ZIP): 02142
19
20 (ii) TITLE OF INVENTION: TREATMENT FOR INSULIN DEPENDENT DIABETES
21
22 (iii) NUMBER OF SEQUENCES: 15
23
24 (iv) COMPUTER READABLE FORM:
25 (A) MEDIUM TYPE: Floppy disk
26 (B) COMPUTER: IBM PC compatible
27 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
28 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
29
30 (v) CURRENT APPLICATION DATA:
31 (A) APPLICATION NUMBER: US 000000 (BGP-151CP)
32 (vi) PRIOR APPLICATION DATA: (B) FILING DATE: *Leading*
33 (A) APPLICATION NUMBER: PCT/US94/01456
34 (B) FILING DATE: 09-FEB-1994
35 (vii) PRIOR APPLICATION DATA:
36 (A) APPLICATION NUMBER: US 08/029,330
37 (B) FILING DATE: 09-FEB-1993
38
39
40 (2) INFORMATION FOR SEQ ID NO: 1:
41
42 (i) SEQUENCE CHARACTERISTICS:
43 (A) LENGTH: 360 base pairs
44 (B) TYPE: nucleic acid
45 (C) STRANDEDNESS: single
46 (D) TOPOLOGY: linear

Please see, also,
back pages. Per
1.824 of Sequence Rules,
the computer readable
form shall contain a
single
file on
which is
recorded on
printable
copy of
the
sequence
Listing.

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/447,118ADATE: 02/28/97
TIME: 18:30:06

INPUT SET: S15870.raw

100
101 (i) SEQUENCE CHARACTERISTICS:
102 (A) LENGTH: 120 amino acids
103 (B) TYPE: amino acid
104 (D) TOPOLOGY: linear
105
106 (ii) MOLECULE TYPE: protein
107 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
108
109 Val Lys Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser
110 1 5 10 15
111
112 Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr
113 -20 20 25 28 30 35
114
115 Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile Gly
116 35 40 45
117
118 Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe Gln
119 50 55 60
120
121 Val Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Trp Leu
122 65 70 75 80
123
124 Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala
125 85 90 95
126
127 Asp Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly Gln
128 100 105 110
129
130 Gly Thr Thr Val Thr Val Ser Ser
131 115 120
132
133 (2) INFORMATION FOR SEQ ID NO: 3:
134
135 (i) SEQUENCE CHARACTERISTICS:
136 (A) LENGTH: 318 base pairs
137 (B) TYPE: nucleic acid
138 (C) STRANDEDNESS: single
139 (D) TOPOLOGY: linear
140
141 (ii) MOLECULE TYPE: cDNA
142
143
144 (ix) FEATURE:
145 (A) NAME/KEY: CDS
146 (B) LOCATION: 1..318
147 (D) OTHER INFORMATION:/product= "HP1/2 light
148 chain variable region"
149
150 (ix) FEATURE:
151 (A) NAME/KEY: misc_feature
152 (B) LOCATION: 1

Please delete all TAB codes
between amino acid numbers.
They do not process well in the
CRF program and cause
misalignment. Use
space
characters
instead.

INPUT SET: S15870.raw

325 (2) INFORMATION FOR SEQ ID NO: 7:

326

327 (i) SEQUENCE CHARACTERISTICS:

--> 328 (A) LENGTH: 386 base pairs
329 (B) TYPE: nucleic acid
330 (C) STRANDEDNESS: single
331 (D) TOPOLOGY: linear

332

333 (ii) MOLECULE TYPE: cDNA

334

335

336 (ix) FEATURE:

337 (A) NAME/KEY: CDS
338 (B) LOCATION: 1..386

339

340 (ix) FEATURE:

341 (A) NAME/KEY: sig_peptide
342 (B) LOCATION: 1..57

343

344 (ix) FEATURE:

345 (A) NAME/KEY: mat_peptide
346 (B) LOCATION: 58..386

347

348 (ix) FEATURE:

349 (A) NAME/KEY: misc_feature
350 (B) LOCATION: 1
351 (D) OTHER INFORMATION:/note= "pBAG198 insert: VK2
352 (SVMDY) light chain variable region"

353

354

355 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

356

357 ATG GGT TGG TCC TGC ATC ATC CTG TTC CTG GTT GCT ACC GCT ACC GGT 48
358 Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly

359 -19 -15 -10 -5

360

361 GTC CAC TCC AGC ATC GTG ATG ACC CAG AGC CCA AGC AGC CTG AGC GCC 96
362 Val His Ser Ser Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala
363 1 5 10

364

365 AGC GTG GGT GAC AGA GTG ACC ATC ACC TGT AAG GCC AGT CAG AGT GTG 144
366 Ser Val Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val
367 15 20 25

368

369 ACT AAT GAT GTA GCT TGG TAC CAG CAG AAG CCA GGT AAG GCT CCA AAG 192
370 Thr Asn Asp Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
371 30 35 40 45

372

373 CTG CTG ATC TAC TAT GCA TCC AAT CGC TAC ACT GGT GTG CCA GAT AGA 240
374 Leu Leu Ile Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg
375 50 55 60

376

377 TTC AGC GGT AGC GGT TAT GGT ACC GAC TTC ACC TTC ACC ATC AGC AGC 288

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/447,118ADATE: 02/28/97
TIME: 18:22:45

INPUT SET: S15870.raw

378 Phe Ser Gly Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser
379 65 70 75
380
381 CTC CAG CCA GAG GAC ATC GCC ACC TAC TAC TGC CAG CAG GAT TAT AGC 336
382 Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Asp Tyr Ser
383 80 85 90
384
385 TCT CCG TAC ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA CGT AAG 384
386 Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Lys
387 95 100 105
388
389 TG
390
391

move
386 ← over
from
rt. margin

08/447,18A

- [56] Carlos et al., 1990, Blood 17:965, "Vascular Cell Adhesion molecule-1 (V
- [57] Miller et al., 1993, J. Exp. Med. 178:211.
- [58] L. Osborn et al., "Direct Expression Cloning of Vascular Cell Adhesion M
- [59] J. Devlin et al., "Random Peptide Libraries: A Source of Specific Protei
- [60] J. Scott and G. Smith, "Searching for Peptide Ligands with an Epitope Li
- [61] U.S. Patent 4,833,092, Geysen, "Method For Determining Mimotopes", issue

The foregoing documents are incorporated herein by reference in their en

SEQUENCE LISTING



sample of
large amount
of material
preceding actual
Sequence Listing. Please delete.

These appeared AFTER Segewee Listerij. 08/447,118A

Please delete.

- 4 CLAIMS:
1. A method for the prevention of insulin dependent (type I) diabetes.
 2. A method according to claim 1, wherein the anti-VLA-4 antibody is
 3. A method according to claim 1, wherein the anti-VLA-4 antibody is
 4. A method according to claim 1, wherein the anti-VLA-4 antibody is

Notice of Availability

Applicant Aid for Biotechnology Computer Readable Form (CRF) Sequence Listings Submissions

The Patent and Trademark Office (PTO) has developed a computer program, called Checker, that will aid applicants in identifying and correcting errors prior to making submissions for compliance with the Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (sequence rules: 37 CFR 1.821 through 1.825). (Final rules were published in the *Federal Register* (55 FR 18230) on May 1, 1990, and in the *PTO Official Gazette* (1114 Off.Gaz.PatOffice 29) on May 15, 1990.)

Checker is a DOS-based software program that is intended to assist users in determining whether errors may be present in the sequence listings, and is not intended to guarantee that the submission is error-free.

The most current version of the software will be available via computer downloading (details below). Copies on diskette are also available. Updated software versions will not be automatically mailed out; any updates will be announced in the *PTO Official Gazette*.

The software can be accessed/requested in the following locations:

- 1) Dial-up access to the Patent and Trademark Office Bulletin Board System.
Phone number: 703-305-8950
Cost: Free-of-charge
- 2) Dial-up access through the Internet. FTP site: ftp.uspto.gov
Login as "anonymous". Software is in directory /pub/checker
Cost: Free-of-charge
- 3) For diskette copies, telephone requests to 703-306-2600.
Cost: \$25.00

For Further Information Contact:

Arti Shah at 703-308-4212